SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,328,565 | -76.2% | 91,499 | -65.7% | 0.01% | -75.8% |
Q2 2023 | $5,590,026 | +45.1% | 267,082 | +46.4% | 0.03% | +37.5% |
Q1 2023 | $3,851,887 | -15.5% | 182,381 | +1.8% | 0.02% | -20.0% |
Q4 2022 | $4,557,713 | +175.7% | 179,085 | +160.3% | 0.03% | +172.7% |
Q3 2022 | $1,653,000 | -58.5% | 68,803 | -66.7% | 0.01% | -57.7% |
Q2 2022 | $3,979,000 | +9.1% | 206,818 | -1.4% | 0.03% | +30.0% |
Q1 2022 | $3,647,000 | -17.0% | 209,835 | +4.5% | 0.02% | -13.0% |
Q4 2021 | $4,396,000 | +12.7% | 200,842 | -1.6% | 0.02% | +9.5% |
Q3 2021 | $3,902,000 | +10.3% | 204,181 | -0.9% | 0.02% | +10.5% |
Q2 2021 | $3,537,000 | +29.0% | 206,001 | +68.0% | 0.02% | +26.7% |
Q1 2021 | $2,742,000 | +11.8% | 122,640 | +11.2% | 0.02% | 0.0% |
Q4 2020 | $2,453,000 | +200.6% | 110,309 | +99.5% | 0.02% | +200.0% |
Q3 2020 | $816,000 | -20.8% | 55,289 | -20.4% | 0.01% | -28.6% |
Q2 2020 | $1,030,000 | +35.3% | 69,475 | 0.0% | 0.01% | +40.0% |
Q1 2020 | $761,000 | -34.1% | 69,475 | -47.2% | 0.01% | 0.0% |
Q4 2019 | $1,154,000 | -26.5% | 131,479 | -37.4% | 0.01% | -28.6% |
Q3 2019 | $1,570,000 | -14.9% | 210,156 | +6.0% | 0.01% | -12.5% |
Q2 2019 | $1,845,000 | +137.1% | 198,170 | +33.8% | 0.01% | +166.7% |
Q1 2019 | $778,000 | +9.1% | 148,140 | -7.6% | 0.00% | 0.0% |
Q4 2018 | $713,000 | -43.6% | 160,295 | +2.4% | 0.00% | -40.0% |
Q3 2018 | $1,265,000 | +106.4% | 156,513 | +79.1% | 0.01% | +150.0% |
Q2 2018 | $613,000 | -23.5% | 87,383 | +55.3% | 0.00% | -33.3% |
Q1 2018 | $801,000 | +12.8% | 56,258 | -30.6% | 0.00% | 0.0% |
Q4 2017 | $710,000 | – | 81,056 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |